The feline panleukopenia virus is considered ubiquitous, meaning it is in virtually every place that is not regularly disinfected. The infection is highly contagious among unvaccinated cats. Antibodies against FPLV, produced by the
adaptive immune system, play an important role in the feline response to the virus.
Maternally-derived antibodies (MDA) efficiently protect kittens from fatal infection. This passively acquired immunity is later replaced by an active immune response obtained by vaccination or as a consequence of a natural infection. In kittens, the period of greatest susceptibility to infection is when maternal antibodies are absent, or waning, and vaccine-induced immunity has not yet fully developed. Free-roaming cats are thought to be exposed to the virus during their first year of life. Those that develop a
subclinical infection or survive acute illness mount a robust, long-lasting, protective immune response. It persists long after evidence of the original body secretion has faded away, and can be transported long distances. Like all parvoviruses, FPLV is extremely resistant to inactivation and can survive for longer than one year in a suitable environment. Kitten deaths have been reported in households of fully vaccinated cats, possibly because of exposure to large amounts of virus in the environment. In a recent study,
microRNA responses to FPLV infection were identified in feline kidney cells by sequencing, providing a possible link between miRNA expression and pathogenesis of FPV infection. Infection occurs when the virus enters the body through the mouth or nose. Whether illness results or not depends on the immunity in the victim vs. the number of individual virus particles (i.e. the amount of virus) entering the body. == Clinical signs ==